Compare LOB & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LOB | TYRA |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | 1040 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2014 | 2021 |
| Metric | LOB | TYRA |
|---|---|---|
| Price | $37.24 | $32.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $43.00 | ★ $47.50 |
| AVG Volume (30 Days) | 185.7K | ★ 731.1K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.32% | N/A |
| EPS Growth | ★ 31.95 | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.52 | N/A |
| Revenue Next Year | $16.03 | N/A |
| P/E Ratio | $62.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.96 | $8.75 |
| 52 Week High | $42.89 | $40.65 |
| Indicator | LOB | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 55.26 | 40.05 |
| Support Level | $35.51 | $30.10 |
| Resistance Level | $37.35 | $33.99 |
| Average True Range (ATR) | 0.86 | 1.98 |
| MACD | -0.04 | -0.26 |
| Stochastic Oscillator | 68.62 | 4.68 |
Live Oak Bancshares Inc operates as the bank holding company for the Live Oak Banking Company. The company specializes in lending and deposit-related services to small businesses nationwide. The company identifies and extends lending to credit-worthy borrowers both within specific industries, also called verticals, through expertise within those industries, and more broadly to select borrowers outside of those industries. A portion of the loans originated by the Bank are partially guaranteed by the Small Business Administration under the 7(a) Loan Program and the U.S. Department of Agriculture Rural Energy for America Program, Water and Environmental Program, Business and Industry and Community Facilities loan programs.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.